Table 3.
Patients that stopped bETA for any reason.
| PTS | Sex | Age | DGN | DIS DUR (yy) | oETA (mm) | bETA (mm) | LoE | AE | SF | Measures taken | Outcome after interruption |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 68 | RA | 10 | 26 | 4 | √ | – | – | Swap to a tsDMARD | Clinical improvement |
| 2 | F | 58 | RA | 21 | 34 | 8 | √ | – | – | Swap to an other bDMARD | Partially improvement |
| 3 | F | 85 | RA | 22 | 102 | 6 | √ | – | – | Swap to an other bDMARD | Clinical improvement |
| 4 | M | 69 | RA | 14 | 92 | 7 | – | Psoriasis (new onset) | – | Switch back to originator | Resolved |
| 5 | F | 63 | RA | 16 | 78 | 6 | – | – | Arthralgia worsening | Switch back to originator | Resolved |
| 6 | F | 66 | PsA | 4 | 26 | 8 | √ | – | – | Swich to an other bDMARD; swap to an other bDMARD | Coutaneous rash; clinical improvement |
| 7 | F | 71 | PsA | 18 | 186 | 6 | √ | – | – | Swich to an other bDMARD | Partially improvement |
| 8 | F | 70 | PsA | 17 | 52 | 7 | √ | – | – | Swich to an other bDMARD | Clinical improvement |
| 9 | F | 74 | PsA | 10 | 89 | 1 | – | Cutaneous rash | – | Switch back to originator | Resolved |
| 10 | F | 75 | PsA | 10 | 45 | 4 | – | – | Arthralgia worsening | Switch back to originator | Resolved |
| 11 | M | 58 | AS | 13 | 84 | 4 | √ | – | – | Switch back to originator | Resolved |
PTS patients, DGN diagnosis, DIS DUR disease duration, LoE lack of efficacy, AE adverse event, SF subjective features, yy years, mm months, bDMARD biologic disease-modifying antirheumatic drug, tsDMARD targeted synthetic disease-modifying antirheumatic drug.